PARPi inhibitors in focus BRCAWAY and TALAPRO-2

PARPi therapy is a relatively recent addition to the armamentarium of treatments for mCRPC. Hear about the clinical implications of PARPi-focused trials presented at ASCO 2024, with Professor Merseburger (University Hospital Schleswig-Holstein, Germany). View Video. View transcript.

Complete the form below to receive our regular round-up of the latest clinical news and medical education resources on Medthority, straight to your inbox.

* = required information

Name

Email address

Specialty

By providing your email address, you are opting in to receive our monthly newsletter.

I agree to receive additional communications from Medthority related to my specialty.

We will never share your data, and you can withdraw consent at any time. Read our privacy policy here.

Developed by EPG Health. This content has been developed independently of the sponsor, Pfizer, which has had no editorial input into the content. EPG Health received funding from the sponsor to help provide healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content. This content is intended for healthcare professionals only.